Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.

Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:

Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism

Showing studies that mention “small cell carcinoma”.

Human onlyPositive outcomesSafety signalsTrials2 of 200 studies

ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical

Neuroendocrine tumours of the urinary bladder: recent advances

Histopathology · Jan 2026

neuroendocrine tumour of the urinary bladdersmall cell carcinomalarge cell neuroendocrine carcinomawell-differentiated neuroendocrine tumourparaganglioma

This review summarizes recent advances in the pathology and molecular understanding of neuroendocrine tumours of the urinary bladder. It reports that small cell carcinoma is the most commonly encountered bladder NET and may occur alone or alongside urothelial carcinoma or other histologies. Large-cell neuroendocrine carcinoma is being increasingly recognized but remains incompletely characterized, whereas well-differentiated NETs and paragangliomas of the bladder are rare. The authors state that molecular characterization advances have improved biological understanding and may enable better classification and risk stratification.

Studied with: urothelial carcinoma, other histological subtypes.

Key findings

Small cell carcinoma is the most frequently encountered neuroendocrine tumour of the urinary bladder and may present as either pure or in combination with urothelial carcinoma or other histological subtypes.
Large cell neuroendocrine carcinoma is increasingly recognized in this location, but it is not yet fully characterized.
Well-differentiated NET and paraganglioma of the bladder are rare neuroendocrine neoplasms.
Advances in the molecular characterization of these tumours have enhanced our understanding of their biology and can provide better classification and more accurate risk stratification for clinical decision-making.

Limitations: Narrative review format (no methods, search strategy, or systematic synthesis described in the abstract).; Abstract does not present new primary data or quantitative results.; Abstract provides no details on specific molecular markers, study cohorts, or clinical outcome data..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewInconclusiveLimited evidenceTier 4 · clinical

Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management

Bladder cancer (Amsterdam, Netherlands) · Aug 2025 · narrative review

small cell carcinoma of the bladder (SCCB)

This is a narrative review of small cell carcinoma of the bladder (SCCB), a rare and aggressive subtype that represents under 1% of bladder cancers. The authors summarize clinical presentation, staging, local and systemic management, and molecular insights, noting most treatment regimens are extrapolated from small cell lung cancer and that novel agents are in development. They call for greater preclinical research and increased patient participation in clinical trials.

Key findings

SCCB is a rare, aggressive malignancy accounting for less than 1% of bladder cancers.
The review summarizes epidemiology, cystoscopic and imaging findings, staging methods, local and systemic treatment approaches, and molecular mechanisms underlying SCCB.
Most treatment regimens for SCCB are extrapolated from small cell lung cancer due to shared neuroendocrine features and aggressive phenotype.
Novel agents for SCCB are in clinical development.
The authors recommend increased preclinical research and greater participation of SCCB patients in clinical trials to expand treatment options.

Limitations: Review article with no new primary data reported.; Evidence base is limited and heterogeneous because SCCB is rare (<1% of bladder cancers).; Many treatment recommendations are extrapolated from small cell lung cancer rather than SCCB-specific trials.; Likely lack of large, randomized clinical trials specific to SCCB..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text